Human cells (including the nucleus) on a blue background. Cell line development web page.

Unlocking scale in cell line development with automation

The challenges

Cell Line Development (CLD) is one of the most utilised processes in modern cell biology. 

Whether for biotherapeutics, new technology research, or new screening platforms for cell-based assays, developing high-producing, stable cell lines has become a fundamental part of scientific discovery. But there remain challenges in CLD. 

Automata’s open integrated automation (OIA) solution tackles scale, reproducibility and traceability issues in CLD, allowing end-to-end automation that doesn’t compromise flexibility.

What is open, integrated automation?

Our open integrated automation platform, LINQ, combines three components to create a lab automation solution that works for you: the Automata LINQ bench, the Automata LINQ software, and a world-class service. 

Integrating with most instruments and featuring a modular design, the Automata LINQ bench is easily adaptable for any workflow or any existing lab space.

Unlocking scale

CLD is essentially a numbers game; the more clones you’re able to analyse, the more chance you have of isolating high-performing cell lines with the characteristics you desire. But many conventional approaches to CLD make decisions based on a relatively small dataset.

For example, when the selected clone is passed to process development in biotherapeutics, the starting data points are typically very minimal and the number of clones is small. With automation, and higher-density labware, you are able to seed into many 96 or 384 well plates. 

High throughput whole well imaging and characterisation enables the generation and screening of large numbers of clonal cell lines simply not possible without automation.

Enhancing data and traceability 

With end-to-end automation, it also becomes possible to automatically unify data from multiple sources and instruments with full traceability. Complete datasets tied to clone identifiers can be built and reported back to recording and analytical tools within the digital ecosystem. 

For biologics producing cell lines, this level of data integrity and traceability forms a key part of Clonality Reporting for Food and Drug Administration Investigational New Drug proposals, for example. 

Automation also opens the possibility of layering a multitude of analytical steps that would be unachievable manually, allowing decision-making based on data sets with greater dimensionality.

It becomes possible to include clonality, flow cytometry, product quantitation, and characterisation, along with all the methodology metadata, so a complete dataset can be built around your developed cell line early in the process.

Complete workflows

From cell printing and imaging, through productivity screening and expansion to harvesting and master cell bank creation, it is possible to build a complete end-to-end cell line development platform as one holistic workflow.

Get in touch and find out how we can help your lab automate

Is Automata right for my cell line development lab? 

Here are a few answers to some frequently asked questions